Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Doses of NNC0519-0130 in Healthy Participants and Multiple Subcutaneous and Oral Doses of NNC0519-0130 in Participants With Overweight or Obesity and Participants With Type 2 Diabetes
Latest Information Update: 14 Apr 2025
At a glance
- Drugs NNC 0519 0130 (Primary) ; NNC 0519 0130 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
Most Recent Events
- 30 Apr 2024 Status changed from recruiting to completed.
- 31 Oct 2023 Planned End Date changed from 26 Jan 2024 to 19 Mar 2024.
- 31 Oct 2023 Planned primary completion date changed from 18 Sep 2023 to 19 Mar 2024.